Medline Industries recalled 2,680 bottles of Povidone-Iodine 10% Solution on August 19, 2025. The product is subpotent, posing a risk to users. Consumers should stop use immediately and contact their healthcare provider.
Subpotent drug
Consumers and healthcare providers should stop using this product immediately. Contact Medline Industries, LP or your healthcare provider for guidance. Notification method: Letter
The recalled product is READYPREP PVP, Povidone-Iodine 10% Solution, sold in 1-gallon bottles. The lot number is 24EJA180, with an expiration date of June 1, 2027. It was distributed nationwide in the USA.
The recall was initiated due to the product being classified as a subpotent drug. This means it may not provide the intended antiseptic effects, posing potential health risks.
There have been no reported injuries or incidents associated with this recall. The risk level is classified as high due to the potential for inadequate antiseptic effectiveness.
Stop using the product immediately. Contact Medline Industries or your healthcare provider for guidance on next steps. Consumers will receive notification letters regarding the recall.
For more information, contact Medline Industries at 1-800-633-5463 or visit their website. Additional details can be found at the FDA recall page.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.